Chronic cough in idiopathic pulmonary fibrosis ranks among the most debilitating and treatment-resistant symptoms patients face — one that existing antifibrotic therapies do little to address. A randomized controlled trial now offers a credible pharmacological candidate for this neglected problem, with implications for the roughly 100,000 Americans living with IPF.
The CORAL trial evaluated nalbuphine extended-release, a kappa-opioid receptor agonist and mu-opioid partial antagonist, in IPF patients suffering from chronic cough. The trial used objective 24-hour cough monitoring rather than relying solely on patient-reported outcomes, lending the frequency data methodological credibility. Higher doses of nalbuphine ER produced meaningfully greater reductions in cough frequency compared to placebo at the six-week endpoint, suggesting a dose-response relationship consistent with on-target pharmacological activity. The dual receptor profile is notable: kappa agonism is thought to suppress cough centrally while the partial mu antagonism theoretically moderates classic opioid side effects such as respiratory depression and dependency.
This finding sits at an important intersection of pulmonology and pain pharmacology. Prior attempts to manage IPF-related cough have leaned on off-label use of low-dose morphine or thalidomide, neither of which carries robust trial evidence in this population. Nalbuphine's receptor selectivity could offer a cleaner therapeutic window if the safety profile holds in longer studies. Key limitations warrant caution, however: a six-week window cannot assess durability of effect or long-term tolerability; IPF is a progressive disease, so cough mechanisms may evolve. The trial's correspondence-level publication in JAMA also signals ongoing clinical questions rather than a fully resolved evidence base. For now, this is a genuinely promising but incremental advance — one that moves the field toward targeted cough suppression without resolving questions of optimal dosing, patient selection, or interaction with antifibrotic regimens.